Performance of VTGN VistaGen Therapeutics | 2% in 12m
Compare VTGN with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare VistaGen Therapeutics with its related Sector/Index XBI
Performance Duell VTGN vs XBI
| TimeFrame | VTGN | XBI |
|---|---|---|
| 1 Day | -2.46% | -0.94% |
| 1 Week | -5.41% | -2.69% |
| 1 Month | -10.6% | -0.01% |
| 3 Months | -15.2% | -5.33% |
| 6 Months | 60.1% | 31.03% |
| 12 Months | 2.01% | 3.19% |
| YTD | -15.2% | -2.32% |
| Rel. Perf. 1m | -1.43 | |
| Rel. Perf. 3m | -1.52 | |
| Rel. Perf. 6m | 0.78 | |
| Rel. Perf. 12m | 0.34 |
Is VistaGen Therapeutics a good stock to buy?
Probably not. Based on ValueRay Analyses, VistaGen Therapeutics (NASDAQ:VTGN) is currently (May 2024)
not a good stock to buy. It has a ValueRay Growth Rating of -3.35 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of VTGN as of May 2024 is 4.61. This means that VTGN is currently overvalued and has a potential downside of 5.49% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of VTGN as of May 2024 is 4.61. This means that VTGN is currently overvalued and has a potential downside of 5.49% (Sold with Premium).
Is VTGN a buy, sell or hold?
- Strong Buy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
Values above 0%: VTGN is performing better - Values below 0%: VTGN is underperforming
Compare VTGN with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -6.24% | -12.59% | 40.90% | -26.37% |
| US NASDAQ 100 | QQQ | -5.82% | -11.49% | 42.43% | -34.90% |
| US Dow Jones Industrial 30 | DIA | -7.14% | -14.71% | 43.97% | -18.89% |
| German DAX 40 | DBXD | -8.52% | -15.02% | 38.13% | -15.45% |
| UK FTSE 100 | ISFU | -6.69% | -17.02% | 42.14% | -11.35% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -5.17% | -17.33% | 57.42% | 10.50% |
| Hongkong Hang Seng | HSI | -7.82% | -25.47% | 56.16% | 10.82% |
| Japan Nikkei 225 | EXX7 | -2.81% | -5.68% | 47.24% | -11.55% |
| India NIFTY 50 | INDA | -3.50% | -10.05% | 44.42% | -22.55% |
| Brasil Bovespa | EWZ | -3.18% | -11.72% | 58.83% | -10.54% |
VTGN VistaGen Therapeutics vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -6.01% | -11.20% | 39.74% | -36.24% |
| Consumer Discretionary | XLY | -4.46% | -11.19% | 49.76% | -19.40% |
| Consumer Staples | XLP | -7.65% | -16.41% | 46.19% | -1.58% |
| Energy | XLE | -5.98% | -8.24% | 46.40% | -21.62% |
| Financial | XLF | -7.26% | -15.05% | 35.46% | -31.46% |
| Health Care | XLV | -6.96% | -14.00% | 46.09% | -8.40% |
| Industrial | XLI | -6.76% | -12.89% | 36.57% | -27.75% |
| Materials | XLB | -7.38% | -12.77% | 39.92% | -18.00% |
| Real Estate | XLRE | -7.52% | -12.16% | 47.25% | -3.57% |
| Technology | XLK | -5.71% | -10.69% | 44.46% | -35.26% |
| Utilities | XLU | -9.06% | -21.64% | 38.37% | -4.79% |
| Aerospace & Defense | XAR | -5.73% | -16.94% | 43.76% | -24.96% |
| Biotech | XBI | -2.72% | -10.62% | 29.04% | -1.18% |
| Homebuilder | XHB | -6.02% | -13.77% | 20.36% | -51.13% |
| Retail | XRT | -5.54% | -14.11% | 34.06% | -22.20% |
Does VistaGen Therapeutics outperform its market, is VTGN a Sector Leader?
No, over the last 12 months VistaGen Therapeutics (VTGN) made 2.01%, while its related Sector, the SPDR S&P Biotech (XBI) made 3.19%.
Over the last 3 months VTGN made -15.15%, while XBI made -5.33%.
No, over the last 12 months VistaGen Therapeutics (VTGN) made 2.01%, while its related Sector, the SPDR S&P Biotech (XBI) made 3.19%.
Over the last 3 months VTGN made -15.15%, while XBI made -5.33%.
| Period | VTGN | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -10.63% | -0.01% | 1.96% |
| 3 Months | -15.15% | -5.33% | 4.29% |
| 12 Months | 2.01% | 3.19% | 28.38% |